KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cost of Revenue: 2018-2025

Historic Cost of Revenue for Rigel Pharmaceuticals (RIGL) over the last 7 years, with Sep 2025 value amounting to $4.8 million.

  • Rigel Pharmaceuticals' Cost of Revenue fell 40.78% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 16.86%. This contributed to the annual value of $18.6 million for FY2024, which is 162.26% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Cost of Revenue of $4.8 million as of Q3 2025, which was up 5.53% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Cost of Revenue ranged from a high of $8.0 million in Q3 2024 and a low of $121,000 during Q1 2022.
  • Over the past 3 years, Rigel Pharmaceuticals' median Cost of Revenue value was $3.8 million (recorded in 2023), while the average stood at $3.6 million.
  • In the last 5 years, Rigel Pharmaceuticals' Cost of Revenue slumped by 61.71% in 2022 and then surged by 1,008.19% in 2023.
  • Over the past 5 years, Rigel Pharmaceuticals' Cost of Revenue (Quarterly) stood at $487,000 in 2021, then dropped by 29.77% to $342,000 in 2022, then skyrocketed by 1,008.19% to $3.8 million in 2023, then skyrocketed by 52.74% to $5.8 million in 2024, then tumbled by 40.78% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $4.5 million for Q2 2025, and $4.4 million during Q1 2025.